Chemo for standard-risk childhood leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 1 and 10 years old.
- Your child’s initial white blood cell count must be below 50,000.
- The leukemia must not have spread to the testicles.
- Your child’s kidneys and liver must be working well enough.
- Your child must not have certain genetic changes or other serious conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment approach for children and teens with high-risk acute lymphoblastic leukemia (ALL). It aims to improve outcomes for those with certain genetic changes or cancer that has spread.
This Phase 2 study tests a combination treatment for children, teens, or young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or did not respond to initial therapy. It may help patients who cannot safely receive certain standard medicines like anthracyclines or who cannot tolerate PEG-asparaginase.
This trial tests a treatment plan for newly diagnosed acute lymphoblastic leukemia (ALL) in people ages 16 to 50. It aims to see how well a “pediatric-style” regimen works, but it only fits certain genetic and health profiles.
This trial studies a treatment approach for children and teens newly diagnosed with lymphoblastic lymphoma. It may help doctors choose therapies based on genetic risk information from lab testing done on tumor samples.
This trial uses a standard treatment plan for children who have just been diagnosed with acute lymphoblastic leukemia (ALL). It aims to guide the best initial treatment for certain cell types of ALL and help improve outcomes while avoiding specific higher-risk subtypes.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
Hear when a new Lymphoblastic Leukemia in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.